获得性重型再生障碍性贫血:20世纪与21世纪内科治疗的演变
本文综述获得性再生障碍性贫血(AA)内科治疗的进展,指出该病已从多数致死的难治性疾病转变为可通过造血干细胞移植(HSCT)或免疫抑制治疗(IST)成功治疗的疾病。文章梳理了支持治疗的进步、以抗胸腺细胞球蛋白(ATG)为基础的方案演变,以及血小板生成素受体激动剂(Tpo-RA)在刺激早期造血干细胞方面的作用,并讨论了剂量、时机与联合策略的优化方向。
要点
- AA已从高致死性疾病变为HSCT或IST可成功治疗的疾病。
- ATG是HSCT和IST方案的基础,但增强免疫抑制强度未改善结局。
- Tpo-RA可刺激AA早期HSC,剂量与联合方案仍在优化。
核心结论
- 获得性AA的治疗已取得显著成功,HSCT与IST可使多数患者获得有效治疗。
研究设计与样本
- 本文为综述,聚焦AA内科治疗进展,检索范围未在摘要中报告。
主要发现
- AA中造血干细胞(HSC)减少的机制涉及遗传与免疫改变。
- 支持治疗进步(更好的抗菌药物、更安全的血制品和铁螯合)显著影响AA结局。
- ATG是HSCT和IST方案的基础,但增强免疫抑制效力未带来更好结局。
- 历史上刺激HSC的方法未显效,而Tpo-RA在AA中可有效刺激早期HSC。
关键数值与推荐
- Tpo-RA在AA中 despite 高内源性Tpo水平仍能刺激早期HSC。
- Tpo-RA的剂量、时机及最佳联合方案正在明确中,以最小附加毒性改善HSC扩增。
临床怎么用
- 临床可基于HSCT或IST(以ATG为基础)治疗获得性AA。
- 支持治疗应重视抗菌药物、血制品安全与铁螯合。
- 可考虑Tpo-RA刺激HSC,但需关注剂量、时机与联合方案。
局限性
- 摘要未报告综述的检索范围与纳入标准。
- 摘要未报告具体研究样本量、疗效数值或统计学结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The progress in aplastic anaemia (AA) management is one of success. Once an obscure entity resulting in death in most affected can now be successfully treated with either haematopoietic stem cell transplantation (HSCT) or immunosuppressive therapy (IST). The mechanisms that underly the diminution of haematopoietic stem cells (HSCs) are now better elucidated, and include genetics and immunological alterations. Advances in supportive care with better antimicrobials, safer blood products and iron chelation have greatly impacted AA outcomes. Working somewhat 'mysteriously', anti-thymocyte globulin (ATG) forms the base for both HSCT and IST protocols. Efforts to augment immunosuppression potency have not, unfortunately, led to better outcomes. Stimulating HSCs, an often-sought approach, has not been effective historically. The thrombopoietin receptor agonists (Tpo-RA) have been effective in stimulating early HSCs in AA despite the high endogenous Tpo levels. Dosing, timing and best combinations with Tpo-RAs are being defined to improve HSCs expansion in AA with minimal added toxicity. The more comprehensive access and advances in HSCT and IST protocols are likely to benefit AA patients worldwide. The focus of this review will be on the medical treatment advances in AA.
引用
- Scheinberg P. Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries. Br J Haematol. 2021. PMID: 33855695. doi:10.1111/bjh.17403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。